ReviewBiological psychiatry2026
GluN2D NMDA Receptors: Bridging Physiology and Pathology.
Review in Biological psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
NMDA receptors (NMDARs) are pivotal mediators of excitatory neurotransmission and play crucial roles in normal brain development, synaptic plasticity, and higher-order cognitive functions such as learning and memory. Their involvement in such diverse physiological processes arises from the complex regulation of synaptic and neuronal activity, primarily conferred by subunit heterogeneity. The combination of different GluN2 subunits, each with distinct spatiotemporal expression patterns, localization within neuronal circuits, and unique biophysical and pharmacological properties, enables NMDARs to finely tune synaptic responses across various brain regions and developmental stages. Among these, the GluN2D subunit has remained relatively understudied compared with the extensively characterized GluN2A and GluN2B. Nonetheless, recent advances have brought renewed attention to their specialized roles. GluN2D is broadly expressed during embryonic and early postnatal development, but its expression becomes more spatially restricted in the adult brain, where it is predominantly found in subpopulations of GABAergic (gamma-aminobutyric acidergic) interneurons. This developmentally regulated and cell type-specific expression pattern suggests that GluN2D contributes to the maturation and maintenance of excitatory-inhibitory balance and coordinated network activity. Although early progress in understanding GluN2D function was limited by a lack of selective tools and suitable models, recent breakthroughs in pharmacology, transgenic mouse models, and human genetic studies have significantly facilitated detailed investigations into the physiological and pathological roles of this subunit. In this review, we examine the unique physiological and pharmacological properties of GluN2D and underscore its growing significance in the context of neuropsychiatric and neurological disorders.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.